
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated significant growth in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,669 units in the latest report, indicating strong demand for its myoelectric orthotic devices. The recent positive ruling from CMS to include the MyoPro in Medicare Part B benefits presents a substantial expansion opportunity in the Medicare market, potentially enhancing revenue streams. Additionally, with orthotics and prosthetics (O&P) providers accounting for approximately 22% of revenue expected in 2024, Myomo is strategically positioning itself to capitalize on the growing Medicare market and redirect its growth efforts effectively.
Bears say
Myomo Inc has significantly lowered its 2025 revenue guidance from $50–53 million to $40–42 million, indicating potential challenges in its financial performance. Additionally, the company's marketing efforts and quality of pipeline additions have been disappointing, negatively impacting lead quality and conversion rates. The authorized insurance backlog has decreased from 272 in Q4 to 208, suggesting a decline in demand for its myoelectric orthosis products and contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares